

# Jean-Pierre Delord

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1103485/publications.pdf>

Version: 2024-02-01

146  
papers

11,563  
citations

61945

43  
h-index

30058

103  
g-index

152  
all docs

152  
docs citations

152  
times ranked

17922  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2762-2770.	3.2	10
2	Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. , 2022, 10, e004076.		30
3	Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. <i>European Journal of Cancer</i> , 2022, 171, 259-268.	1.3	19
4	Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. <i>Targeted Oncology</i> , 2021, 16, 37-46.	1.7	5
5	Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. <i>Clinical Cancer Research</i> , 2021, 27, 1037-1047.	3.2	55
6	Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. <i>Targeted Oncology</i> , 2021, 16, 47-57.	1.7	8
7	Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. <i>Clinical Cancer Research</i> , 2021, 27, 3360-3369.	3.2	47
8	Pancreatic cancer intrinsic PI3K $\delta$ activity accelerates metastasis and rewires macrophage component. <i>EMBO Molecular Medicine</i> , 2021, 13, e13502.	3.3	19
9	PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells. <i>JCI Insight</i> , 2021, 6, .	2.3	64
10	Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors. <i>Journal of Molecular Cell Biology</i> , 2020, 12, 202-215.	1.5	47
11	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1-10.	0.8	1,740
12	Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2020, 26, 6429-6436.	3.2	14
13	Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour. <i>European Journal of Cancer</i> , 2020, 141, 162-170.	1.3	29
14	Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. , 2020, 8, e001153.		37
15	Improving communication between the general practitioner and the oncologist: a key role in coordinating care for patients suffering from cancer. <i>BMC Cancer</i> , 2020, 20, 495.	1.1	15
16	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. <i>Investigational New Drugs</i> , 2020, 38, 1774-1783.	1.2	13
17	Circulating CD14 <sup>high</sup> CD16 <sup>low</sup> intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression. , 2020, 8, e000472.		17
18	Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1761.	1.7	8

#	ARTICLE	IF	CITATIONS
19	Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies. <i>Cancer Immunology Research</i> , 2020, 8, 869-882.	1.6	16
20	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2124-2130.	3.2	132
21	Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEK Prospective Study. <i>Clinical Chemistry</i> , 2019, 65, 1267-1275.	1.5	38
22	Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2825-2834.	0.8	280
23	Immune checkpoint inhibitors: a potential treatment breakthrough for metastatic triple-negative breast cancer?. <i>Women's Health Investigation</i> , 2019, 2, 2-2.	0.0	0
24	Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1357-1366.	1.1	19
25	The GIRAFE phase II trial on MVCT-based "volumes of the day" and "dose of the day" addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer. <i>Clinical and Translational Radiation Oncology</i> , 2019, 16, 34-39.	0.9	5
26	Definitive radiochemotherapy or initial surgery for oropharyngeal cancer. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 496-503.	1.0	12
27	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1470-1478.	0.8	671
28	Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging. <i>BMC Cancer</i> , 2019, 19, 167.	1.1	39
29	Anti-TNF, a magic bullet in cancer immunotherapy?. , 2019, 7, 303.		21
30	Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 74.	3.4	557
31	Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer. <i>Investigational New Drugs</i> , 2019, 37, 693-701.	1.2	9
32	Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma. <i>JAMA Oncology</i> , 2019, 5, 351.	3.4	127
33	First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 674-683.	1.2	16
34	Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1 "Low/Negative Recurrent or Metastatic HNSCC. <i>JAMA Oncology</i> , 2019, 5, 195.	3.4	235
35	Abstract 4079: EVT801: a selective VEGFR3 inhibitor with the potential for combination with immune-checkpoint therapies, preclinical evidences and plans for first-in-human evaluation. , 2019, , .		1
36	Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies. <i>Cancer Research</i> , 2019, 79, CT073-CT073.	0.4	17

#	ARTICLE	IF	CITATIONS
37	MEDIPLEX: A phase I study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).. Journal of Clinical Oncology, 2019, 37, 2579-2579.	0.8	38
38	Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study.. Journal of Clinical Oncology, 2019, 37, 190-190.	0.8	18
39	First-in-human first-in-class phase I trial of murilantamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and paclitaxel (P) in AMHRII-expressing advanced/metastatic gynecological cancer patients (pts).. Journal of Clinical Oncology, 2019, 37, 2521-2521.	0.8	0
40	Abstract 5001: Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients with resectable squamous cell carcinoma of the head and neck. , 2019, , .		0
41	Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1083-1088.	0.6	145
42	Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. British Journal of Cancer, 2018, 118, 344-352.	2.9	7
43	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptorâ€“Positive/Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer. Clinical Cancer Research, 2018, 24, 2804-2811.	3.2	249
44	Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Nonâ€“Small-cell Lung Cancer: A Phase I Study. Clinical Lung Cancer, 2018, 19, e277-e285.	1.1	19
45	Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial. JCO Precision Oncology, 2018, 2, 1-11.	1.5	0
46	Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. Journal of Clinical Oncology, 2018, 36, 3007-3014.	0.8	184
47	Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 979-986.	1.1	10
48	Addressing heterogeneity in the design of phase II clinical trials in geriatric oncology. European Journal of Cancer, 2018, 103, 120-126.	1.3	8
49	Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors. Investigational New Drugs, 2018, 36, 1044-1059.	1.2	0
50	Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1â€“3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with<i>FGFR3</i>Alterations. Cancer Discovery, 2018, 8, 812-821.	7.7	206
51	Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma. , 2018, , .		4
52	Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors. Cancer Research, 2018, 78, CT180-CT180.	0.4	44
53	Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.. Journal of Clinical Oncology, 2018, 36, 5522-5522.	0.8	59
54	A first-in-human study of monoclonal antibody GM102 in patients with anti-Mullerian-hormone-receptor II (AMHRII) positive gynecological cancers.. Journal of Clinical Oncology, 2018, 36, 5542-5542.	0.8	3

#	ARTICLE	IF	CITATIONS
55	Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.. Journal of Clinical Oncology, 2018, 36, TPS6094-TPS6094.	0.8	5
56	Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.. Journal of Clinical Oncology, 2018, 36, 166-166.	0.8	5
57	Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. Journal of Clinical Oncology, 2017, 35, 157-165.	0.8	345
58	Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. Clinical Cancer Research, 2017, 23, 5339-5348.	3.2	142
59	A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discovery, 2017, 7, 610-619.	7.7	194
60	A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. European Journal of Cancer, 2017, 76, 110-117.	1.3	89
61	A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 556-566.	0.5	40
62	Comparison of variable selection methods for high-dimensional survival data with competing events. Computers in Biology and Medicine, 2017, 91, 159-167.	3.9	17
63	First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours. European Journal of Cancer, 2017, 86, 240-247.	1.3	14
64	Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study. European Journal of Cancer, 2017, 85, 39-48.	1.3	2
65	Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination. Melanoma Research, 2017, 27, 485-491.	0.6	88
66	Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. Cancer Research, 2017, 77, 2986-2986.	0.4	89
67	Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC). Cancer Research, 2017, 77, CT074-CT074.	0.4	106
68	Abstract CT106: Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression. Cancer Research, 2017, 77, CT106-CT106.	0.4	16
69	SHIVA: Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer Overall survival (OS) analysis.. Journal of Clinical Oncology, 2017, 35, 11515-11515.	0.8	2
70	Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.. Journal of Clinical Oncology, 2017, 35, 3071-3071.	0.8	107
71	PREDICTOR (UNICANCER GEP11): Randomized phase II study of preoperative afatinib in untreated head and neck squamous cell carcinoma (HNSCC) patients.. Journal of Clinical Oncology, 2017, 35, 6021-6021.	0.8	4
72	An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC).. Journal of Clinical Oncology, 2017, 35, 6025-6025.	0.8	25

#	ARTICLE	IF	CITATIONS
73	Development of Photoonycholysis with Vandetanib Therapy. <i>Skin Appendage Disorders</i> , 2016, 2, 146-151.	0.5	8
74	Early Trial Discontinuation in Toxicity-Driven, Dose-Escalating, Phase I Cancer Trials: Occurrence, Outcomes and Predictive Factors. <i>Pharmaceutical Medicine</i> , 2016, 30, 49-55.	1.0	0
75	Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung. <i>Clinical Lung Cancer</i> , 2016, 17, 391-397.	1.1	75
76	Primary care physicians and oncologists are partners in cancer announcement. <i>Supportive Care in Cancer</i> , 2016, 24, 2473-2479.	1.0	12
77	Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. <i>Cancer Discovery</i> , 2016, 6, 492-500.	7.7	319
78	F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer. <i>Cancer Letters</i> , 2016, 370, 10-18.	3.2	17
79	A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2511-2511.	0.8	28
80	SHIVA: Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer PFS ratio from patients who crossed-over.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2535-2535.	0.8	1
81	Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6017-6017.	0.8	7
82	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8503-8503.	0.8	43
83	Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients (pts) with recurrent glioblastoma (GB).. <i>Journal of Clinical Oncology</i> , 2016, 34, e14123-e14123.	0.8	17
84	Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. <i>BMC Cancer</i> , 2015, 15, 700.	1.1	37
85	Acute skin reaction suggestive of pembrolizumab-induced radiosensitization. <i>Melanoma Research</i> , 2015, 25, 555-558.	0.6	35
86	CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 949-956.	5.1	298
87	Intensity-modulated radiotherapy for laryngeal and hypopharyngeal cancer. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 225-233.	1.0	17
88	Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: Are MRI or 18F-FDG PET/CT able to provide an accurate prediction of long-term outcome?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 397-408.	3.3	22
89	Guideline sheets on the side effects of anticancer drugs are useful for general practitioners. <i>Supportive Care in Cancer</i> , 2015, 23, 3473-3480.	1.0	19
90	CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 2753-2762.	3.2	42

#	ARTICLE	IF	CITATIONS
91	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1324-1334.	5.1	897
92	A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2015, 33, 138-147.	1.2	20
93	Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). <i>Cancer Research</i> , 2015, 75, 2859-2859.	0.4	128
94	Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the $\mu$ -specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer. <i>Cancer Research</i> , 2015, 75, CT136-CT136.	0.4	4
95	Abstract PD1-6: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. <i>Cancer Research</i> , 2015, 75, PD1-6-PD1-6.	0.4	25
96	Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3005-3005.	0.8	28
97	Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY" phase 1-2 trial. <i>Oncotarget</i> , 2015, 6, 12796-12808.	0.8	56
98	Abstract PR04: Targeting tumor-associated macrophages with a novel anti-CSF1R antibody in cancer patients. , 2015, , .		0
99	Could tumor growth rate provide useful information to predict the efficacy of eribulin?. <i>Journal of Clinical Oncology</i> , 2015, 33, e12028-e12028.	0.8	0
100	A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS2604-TPS2604.	0.8	1
101	Abstract 2428: Translational study of F14512, a novel vectorised epipodophyllotoxin, which demonstrates a marked activity on ovarian cancer models from patients. , 2015, , .		0
102	Abstract 2700: The IAP inhibitor Debio 1143 reverses carboplatin resistance in ovarian cancer cells by inducing both apoptosis and necroptosis. , 2015, , .		1
103	Emerging new anticancer therapies in 2013. <i>Current Opinion in Oncology</i> , 2014, 26, 357-362.	1.1	2
104	Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 17-39.	2.7	156
105	Evaluation of the effects of hyaluronic acid-carboxymethyl cellulose barrier on ovarian tumor progression. <i>Journal of Ovarian Research</i> , 2014, 7, 40.	1.3	20
106	Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. <i>Cancer Cell</i> , 2014, 25, 846-859.	7.7	1,083
107	Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 496-505.	1.3	26
108	Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. <i>Cancer Research</i> , 2014, 74, CT326-CT326.	0.4	62

#	ARTICLE	IF	CITATIONS
109	Phase 1 study of RG7155, a novel anti-CSF1R antibody, in patients with locally advanced pigmented villonodular synovitis (PVNS).. Journal of Clinical Oncology, 2014, 32, 10504-10504.	0.8	6
110	Targeting <i>FGFR1</i> -amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398.. Journal of Clinical Oncology, 2014, 32, 8034-8034.	0.8	27
111	Final results from the phase I study expansion cohort of Debio0932, an oral HSP90 inhibitor, in patients with solid tumors.. Journal of Clinical Oncology, 2014, 32, 2550-2550.	0.8	0
112	A phase I/II randomized study of Debio1143 combined with concurrent chemoradiation therapy (CCRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).. Journal of Clinical Oncology, 2014, 32, TPS6097-TPS6097.	0.8	1
113	Phase I dose-escalation study of an oral administration of the pan-histone deacetylase inhibitor abexinostat combined with a fixed dose of doxorubicin in patients with solid tumors.. Journal of Clinical Oncology, 2014, 32, 2575-2575.	0.8	0
114	Predictor: Randomized phase II study of preoperative afatinib in untreated nonmetastatic head and neck squamous cell carcinoma patients (HNSCC) aiming at identifying predictive and pharmacodynamic biomarkers of efficacy.. Journal of Clinical Oncology, 2014, 32, TPS6105-TPS6105.	0.8	0
115	Abstract 2940: Comprehensive biomarker program demonstrates proof of mechanism and modulation of the tumor microenvironment due to RG7155, a novel therapeutic antibody targeting tumor associated macrophages. , 2014, , .		0
116	Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma. Head and Neck, 2013, 35, 809-818.	0.9	5
117	A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 900-909.	1.2	20
118	Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment. SpringerPlus, 2013, 2, 679.	1.2	8
119	Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. Investigational New Drugs, 2013, 31, 1207-1216.	1.2	32
120	Drugs and Cancer: an Analysis of the French Pharmacovigilance Database. Therapie, 2013, 68, 149-154.	0.6	3
121	Abstract A72: A first-in-man Phase I study of the galectin-1 (gal-1) inhibitor OTX008 given subcutaneously as a single agent to patients with advanced solid tumors.. Molecular Cancer Therapeutics, 2013, 12, A72-A72.	1.9	10
122	Abstract A73: A Phase I first-in-human (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870).. , 2013, , .		11
123	Long-term efficacy and pharmacodynamic parameter analysis in pretreated KRAS-mutant metastatic colorectal carcinoma (mCRC) patients treated with RG7160 (GA201), an antibody-dependent cellular cytotoxicity (ADCC)-enhanced monoclonal anti-EGFR antibody.. Journal of Clinical Oncology, 2013, 31, 379-379.	0.8	0
124	Abstract LB-171: Randomized phase II trial comparing therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Preliminary results of the feasibility of the SHIVA trial.. , 2013, , .		0
125	Abstract A68: Activity of the TORC 1/2 kinase inhibitor, CC-223, in hormone receptor positive (HR+) breast cancer cell lines and patients (pts) with genetically characterized HR+ breast cancer in a Phase I clinical trial.. , 2013, , .		0
126	Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. Targeted Oncology, 2012, 7, 253-265.	1.7	57



#	ARTICLE	IF	CITATIONS
127	Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death. <i>International Journal of Molecular Sciences</i> , 2012, 13, 9545-9571.	1.8	228
128	Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study. <i>Clinical Colorectal Cancer</i> , 2012, 11, 38-44.	1.0	29
129	Abstract 725: eIF4E/4eBP-1 as predictive factor(s) of response to EGFR targeted drug in head and neck cancer. , 2012, , .		0
130	Unexpected High Levels of Vorinostat when Combined with Vinorelbine in Patients with Advanced Cancer. <i>Current Clinical Pharmacology</i> , 2011, 6, 274-279.	0.2	4
131	Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2011, 29, 3783-3790.	0.8	76
132	Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in Children. <i>Clinical Cancer Research</i> , 2011, 17, 4862-4871.	3.2	35
133	HFS-14, a Specific Quality of Life Scale Developed for Patients Suffering from Handâ€œFoot Syndrome. <i>Oncologist</i> , 2011, 16, 1469-1478.	1.9	82
134	Formation of the eIF4F Translationâ€œInitiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors. <i>Cancer Research</i> , 2011, 71, 4068-4073.	0.4	49
135	Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. <i>Anticancer Research</i> , 2011, 31, 359-66.	0.5	15
136	Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. <i>Investigational New Drugs</i> , 2010, 28, 76-82.	1.2	26
137	Efficacy of Sunitinib in Advanced Medullary Thyroid Carcinoma: Intermediate Results of Phase II THYSU. <i>Oncologist</i> , 2010, 15, 212-213.	1.9	55
138	Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 4434-4445.	3.2	27
139	Vinflunine: A New Microtubule Inhibitor Agent. <i>Clinical Cancer Research</i> , 2008, 14, 1625-1632.	3.2	104
140	Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 7086-7092.	3.2	68
141	Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 3415-3420.	0.8	217
142	In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 709-718.	1.1	86
143	Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 189-194.	1.1	1
144	Serum Cystatin C is a Better Marker of Topotecan Clearance than Serum Creatinine. <i>Clinical Cancer Research</i> , 2005, 11, 3038-3044.	3.2	31

#	ARTICLE	IF	CITATIONS
145	Toxicity patterns of cytotoxic drugs. <i>Investigational New Drugs</i> , 2003, 21, 141-148.	1.2	67
146	Population pharmacokinetics of oxaliplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 127-131.	1.1	33